Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Other Accumulated Expenses (2016 - 2021)

Historic Other Accumulated Expenses for Marimed (MRMD) over the last 8 years, with Q4 2021 value amounting to $2000.0.

  • Marimed's Other Accumulated Expenses fell 9153.98% to $2000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $2000.0, marking a year-over-year decrease of 9153.98%. This contributed to the annual value of $2000.0 for FY2021, which is 9153.98% down from last year.
  • According to the latest figures from Q4 2021, Marimed's Other Accumulated Expenses is $2000.0, which was down 9153.98% from $23640.0 recorded in Q4 2020.
  • In the past 5 years, Marimed's Other Accumulated Expenses registered a high of $1.6 million during Q1 2020, and its lowest value of $2000.0 during Q4 2021.
  • Its 4-year average for Other Accumulated Expenses is $659275.7, with a median of $225000.0 in 2017.
  • Examining YoY changes over the last 5 years, Marimed's Other Accumulated Expenses showed a top increase of 66032.39% in 2020 and a maximum decrease of 9724.53% in 2020.
  • Marimed's Other Accumulated Expenses (Quarter) stood at $225000.0 in 2017, then skyrocketed by 281.41% to $858176.0 in 2019, then crashed by 97.25% to $23640.0 in 2020, then plummeted by 91.54% to $2000.0 in 2021.
  • Its Other Accumulated Expenses stands at $2000.0 for Q4 2021, versus $23640.0 for Q4 2020 and $1.5 million for Q3 2020.